The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bipolar Disorder Market Research Report 2025
Synopsis
Bipolar disorder (formerly called manic-depressive illness or manic depression) is a mental disorder that causes unusual shifts in mood, energy, activity levels, concentration, and the ability to carry out day-to-day tasks.
The global Bipolar Disorder market was valued at US$ 5781 million in 2023 and is anticipated to reach US$ 6994.7 million by 2030, witnessing a CAGR of 2.7% during the forecast period 2024-2030.
North American market for Bipolar Disorder is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bipolar Disorder is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Bipolar Disorder in Mood Stabilizers is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Bipolar Disorder include Glaxo SmithKline (GSK), Pfizer Inc., Janssen Pharmaceuticals, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc., Otsuka Holdings Ltd and AstraZeneca, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bipolar Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bipolar Disorder.
Report Scope
The Bipolar Disorder market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bipolar Disorder market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bipolar Disorder companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Glaxo SmithKline (GSK)
Pfizer Inc.
Janssen Pharmaceuticals
Eli Lilly
Allergan Plc.
Novartis AG
AbbVie Inc.
Otsuka Holdings Ltd
AstraZeneca
Segment by Type
Bipolar I Disorder
Bipolar II Disorder
Cyclothymic Disorder
Segment by Application
Mood Stabilizers
Anticonvulsants
Antipsychotic drugs
Antidepressant drugs
Antianxiety drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bipolar Disorder companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Bipolar disorder (formerly called manic-depressive illness or manic depression) is a mental disorder that causes unusual shifts in mood, energy, activity levels, concentration, and the ability to carry out day-to-day tasks.
The global Bipolar Disorder market was valued at US$ 5781 million in 2023 and is anticipated to reach US$ 6994.7 million by 2030, witnessing a CAGR of 2.7% during the forecast period 2024-2030.
North American market for Bipolar Disorder is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bipolar Disorder is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Bipolar Disorder in Mood Stabilizers is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Bipolar Disorder include Glaxo SmithKline (GSK), Pfizer Inc., Janssen Pharmaceuticals, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc., Otsuka Holdings Ltd and AstraZeneca, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bipolar Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bipolar Disorder.
Report Scope
The Bipolar Disorder market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bipolar Disorder market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bipolar Disorder companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Glaxo SmithKline (GSK)
Pfizer Inc.
Janssen Pharmaceuticals
Eli Lilly
Allergan Plc.
Novartis AG
AbbVie Inc.
Otsuka Holdings Ltd
AstraZeneca
Segment by Type
Bipolar I Disorder
Bipolar II Disorder
Cyclothymic Disorder
Segment by Application
Mood Stabilizers
Anticonvulsants
Antipsychotic drugs
Antidepressant drugs
Antianxiety drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bipolar Disorder companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bipolar Disorder Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Bipolar I Disorder
1.2.3 Bipolar II Disorder
1.2.4 Cyclothymic Disorder
1.3 Market by Application
1.3.1 Global Bipolar Disorder Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Mood Stabilizers
1.3.3 Anticonvulsants
1.3.4 Antipsychotic drugs
1.3.5 Antidepressant drugs
1.3.6 Antianxiety drugs
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bipolar Disorder Market Perspective (2019-2030)
2.2 Bipolar Disorder Growth Trends by Region
2.2.1 Global Bipolar Disorder Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Bipolar Disorder Historic Market Size by Region (2019-2024)
2.2.3 Bipolar Disorder Forecasted Market Size by Region (2025-2030)
2.3 Bipolar Disorder Market Dynamics
2.3.1 Bipolar Disorder Industry Trends
2.3.2 Bipolar Disorder Market Drivers
2.3.3 Bipolar Disorder Market Challenges
2.3.4 Bipolar Disorder Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bipolar Disorder Players by Revenue
3.1.1 Global Top Bipolar Disorder Players by Revenue (2019-2024)
3.1.2 Global Bipolar Disorder Revenue Market Share by Players (2019-2024)
3.2 Global Bipolar Disorder Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bipolar Disorder Revenue
3.4 Global Bipolar Disorder Market Concentration Ratio
3.4.1 Global Bipolar Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bipolar Disorder Revenue in 2023
3.5 Bipolar Disorder Key Players Head office and Area Served
3.6 Key Players Bipolar Disorder Product Solution and Service
3.7 Date of Enter into Bipolar Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bipolar Disorder Breakdown Data by Type
4.1 Global Bipolar Disorder Historic Market Size by Type (2019-2024)
4.2 Global Bipolar Disorder Forecasted Market Size by Type (2025-2030)
5 Bipolar Disorder Breakdown Data by Application
5.1 Global Bipolar Disorder Historic Market Size by Application (2019-2024)
5.2 Global Bipolar Disorder Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Bipolar Disorder Market Size (2019-2030)
6.2 North America Bipolar Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Bipolar Disorder Market Size by Country (2019-2024)
6.4 North America Bipolar Disorder Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bipolar Disorder Market Size (2019-2030)
7.2 Europe Bipolar Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Bipolar Disorder Market Size by Country (2019-2024)
7.4 Europe Bipolar Disorder Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bipolar Disorder Market Size (2019-2030)
8.2 Asia-Pacific Bipolar Disorder Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Bipolar Disorder Market Size by Region (2019-2024)
8.4 Asia-Pacific Bipolar Disorder Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bipolar Disorder Market Size (2019-2030)
9.2 Latin America Bipolar Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Bipolar Disorder Market Size by Country (2019-2024)
9.4 Latin America Bipolar Disorder Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bipolar Disorder Market Size (2019-2030)
10.2 Middle East & Africa Bipolar Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Bipolar Disorder Market Size by Country (2019-2024)
10.4 Middle East & Africa Bipolar Disorder Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Glaxo SmithKline (GSK)
11.1.1 Glaxo SmithKline (GSK) Company Detail
11.1.2 Glaxo SmithKline (GSK) Business Overview
11.1.3 Glaxo SmithKline (GSK) Bipolar Disorder Introduction
11.1.4 Glaxo SmithKline (GSK) Revenue in Bipolar Disorder Business (2019-2024)
11.1.5 Glaxo SmithKline (GSK) Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Detail
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Bipolar Disorder Introduction
11.2.4 Pfizer Inc. Revenue in Bipolar Disorder Business (2019-2024)
11.2.5 Pfizer Inc. Recent Development
11.3 Janssen Pharmaceuticals
11.3.1 Janssen Pharmaceuticals Company Detail
11.3.2 Janssen Pharmaceuticals Business Overview
11.3.3 Janssen Pharmaceuticals Bipolar Disorder Introduction
11.3.4 Janssen Pharmaceuticals Revenue in Bipolar Disorder Business (2019-2024)
11.3.5 Janssen Pharmaceuticals Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Bipolar Disorder Introduction
11.4.4 Eli Lilly Revenue in Bipolar Disorder Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 Allergan Plc.
11.5.1 Allergan Plc. Company Detail
11.5.2 Allergan Plc. Business Overview
11.5.3 Allergan Plc. Bipolar Disorder Introduction
11.5.4 Allergan Plc. Revenue in Bipolar Disorder Business (2019-2024)
11.5.5 Allergan Plc. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Detail
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Bipolar Disorder Introduction
11.6.4 Novartis AG Revenue in Bipolar Disorder Business (2019-2024)
11.6.5 Novartis AG Recent Development
11.7 AbbVie Inc.
11.7.1 AbbVie Inc. Company Detail
11.7.2 AbbVie Inc. Business Overview
11.7.3 AbbVie Inc. Bipolar Disorder Introduction
11.7.4 AbbVie Inc. Revenue in Bipolar Disorder Business (2019-2024)
11.7.5 AbbVie Inc. Recent Development
11.8 Otsuka Holdings Ltd
11.8.1 Otsuka Holdings Ltd Company Detail
11.8.2 Otsuka Holdings Ltd Business Overview
11.8.3 Otsuka Holdings Ltd Bipolar Disorder Introduction
11.8.4 Otsuka Holdings Ltd Revenue in Bipolar Disorder Business (2019-2024)
11.8.5 Otsuka Holdings Ltd Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Detail
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Bipolar Disorder Introduction
11.9.4 AstraZeneca Revenue in Bipolar Disorder Business (2019-2024)
11.9.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
